Literature DB >> 12572921

IL-15 is elevated in sera of patients with relapsing-remitting multiple sclerosis.

Jacek Losy1, Adam Niezgoda, Jarosław Zaremba.   

Abstract

Interleukin-15 is a novel cytokine produced by monocytes/macrophages and sharing several biological activities with IL-2. IL-15 induces T cell proliferation, enhances natural killer (NK) cell cytotoxicity and also stimulates B cells to proliferate and secrete immunoglobulins. The purpose of our study was to measure IL-15 levels in the serum and CSF of 21 patients with relapsing-remitting form of MS, 9 with active gadolinium enhancing lesions in MRI, 12 without enhancing MRI lesions and to compare the results with the control group. IL-15 levels were measured by ELISA. We found a significant increase of IL-15 in the sera of patients with MS in comparison with the control group consisting of 8 patients with tension headache. IL-15 serum levels were highest in patients with active, gadolinium enhancing lesions. IL-15 CSF levels were low and there was no difference between studied groups. The results may suggest the contribution of IL-15 in the immunopathogenesis of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12572921

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  11 in total

1.  Cerebral interleukin-15 shows upregulation and beneficial effects in experimental autoimmune encephalomyelitis.

Authors:  Xiaojun Wu; Weihong Pan; Yi He; Hung Hsuchou; Abba J Kastin
Journal:  J Neuroimmunol       Date:  2010-04-28       Impact factor: 3.478

2.  The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes.

Authors:  Pushpa Pandiyan; Xiang-Ping Yang; Senthil S Saravanamuthu; Lixin Zheng; Satoru Ishihara; John J O'Shea; Michael J Lenardo
Journal:  J Immunol       Date:  2012-09-19       Impact factor: 5.422

3.  IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells.

Authors:  Ping Yu; Richard N Bamford; Thomas A Waldmann
Journal:  Eur J Immunol       Date:  2014-11       Impact factor: 5.532

4.  Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.

Authors:  Deborah L Hodge; Jun Yang; Matthew D Buschman; Paul M Schaughency; Hong Dang; William Bere; Yili Yang; Ram Savan; Jeff J Subleski; Xiao-Ming Yin; Thomas P Loughran; Howard A Young
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

Review 5.  IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction.

Authors:  Bana Jabri; Valérie Abadie
Journal:  Nat Rev Immunol       Date:  2015-11-16       Impact factor: 53.106

Review 6.  IL-15: a central regulator of celiac disease immunopathology.

Authors:  Valérie Abadie; Bana Jabri
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

7.  An activation-induced IL-15 isoform is a natural antagonist for IL-15 function.

Authors:  Lei Zhao; Bo Hu; Yinsheng Zhang; Yuan Song; Dandan Lin; Yonghao Liu; Yu Mei; Dedy Sandikin; Weiping Sun; Min Zhuang; Haiyan Liu
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

Review 8.  Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases.

Authors:  Thomas A Waldmann
Journal:  Arthritis Res Ther       Date:  2004-06-22       Impact factor: 5.156

9.  High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner.

Authors:  Julia K Polansky; Rajia Bahri; Mylene Divivier; Erwin H Duitman; Christina Vock; Diego A Goyeneche-Patino; Zane Orinska; Silvia Bulfone-Paus
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

10.  Mouse hepatitis virus pathogenesis in the central nervous system is independent of IL-15 and natural killer cells.

Authors:  Jun Zuo; Stephen A Stohlman; Jason B Hoskin; David R Hinton; Roscoe Atkinson; Cornelia C Bergmann
Journal:  Virology       Date:  2006-02-28       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.